Key Points
- CEO Mary Szela sold 4,358 shares on March 11 at an average price of $4.13 for about $17,999, leaving her with 768,931 shares (a ~0.56% ownership reduction).
- Additional insider selling was disclosed — Szela also sold 15,944 shares on March 17 at about $3.85 (~$61.4k) and several other officers reported small sales, highlighting elevated insider selling activity.
- Fundamentals are mixed: TriSalus slightly beat quarterly EPS estimates (‑$0.12 vs. consensus ‑$0.13) but remains unprofitable, has a consensus price target of $7 with mixed analyst ratings, and its shares trade below the 50‑ and 200‑day moving averages.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total transaction of $17,998.54. Following the transaction, the chief executive officer directly owned 768,931 shares in the company, valued at $3,175,685.03. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
TriSalus Life Sciences Trading Up 1.8%
Shares of TLSI stock opened at $3.93 on Friday. The stock has a market cap of $240.95 million, a P/E ratio of -2.15 and a beta of 0.42. TriSalus Life Sciences, Inc. has a 1 year low of $3.42 and a 1 year high of $7.95. The stock has a 50 day simple moving average of $4.91 and a 200 day simple moving average of $5.29.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million. Analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current year.
Hedge Funds Weigh In On TriSalus Life Sciences
Hedge funds and other institutional investors have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey bought a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $29,000. JPMorgan Chase & Co. lifted its position in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after buying an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TriSalus Life Sciences in the second quarter valued at about $47,000. Invesco Ltd. acquired a new stake in TriSalus Life Sciences in the fourth quarter valued at about $72,000. Finally, Abel Hall LLC bought a new position in TriSalus Life Sciences in the fourth quarter valued at about $73,000. Institutional investors own 2.58% of the company's stock.
TriSalus Life Sciences News Summary
Here are the key news stories impacting TriSalus Life Sciences this week:
- Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
- Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
- Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
- Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
- Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Canaccord Genuity Group decreased their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating on the stock in a research report on Friday, March 6th. Wall Street Zen upgraded shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Finally, Zacks Research upgraded shares of TriSalus Life Sciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $7.00.
View Our Latest Analysis on TLSI
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
